Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

Autor: Yingling JM; Idera Pharmaceuticals, Inc., Cambridge, Massachusetts, USA., McMillen WT; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Yan L; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Huang H; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA., Sawyer JS; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Graff J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Clawson DK; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Britt KS; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Anderson BD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Beight DW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Desaiah D; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Lahn MM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Benhadji KA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Lallena MJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Holmgaard RB; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Xu X; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Zhang F; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Iversen PW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Iyer CV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Brekken RA; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA., Kalos MD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA., Driscoll KE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.

Publikováno v: Oncotarget [Oncotarget] 2017 Dec 31; Vol. 9 (6), pp. 6659-6677. Date of Electronic Publication: 2017 Dec 31 (Print Publication: 2018).